Hinge Health, Inc. (HNGE)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 43/100 (MEDIUM), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 14.75% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Hinge Health to announce third quarter 2026 financial results on November 2, 2026
- Hinge Health Growth Outlook Supported by Member Gains, New Products, BofA Says
- Exceptional Earnings and AI Immunity Fuel Hinge Health’s (HNGE) Performance
- Is Hinge Health (HNGE) Still Undervalued As Its Digital Care Growth Draws Attention?
- Jim Cramer Explains Why He Added Hinge Health (HNGE) to His Fantasy Lineup
- Hinge Health Director Kristina Leslie Sells 1,200 Shares for $105,876
- Hinge Health Inc. (HNGE) Up 13.7% Since Last Earnings Report: Can It Continue?
- Jim Cramer Compares Aveanna Healthcare (AVAH) With Hinge Health (HNGE)
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Hinge Health, Inc..
Full HNGE Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.